Floatz logo

rc48-adc

Mesothelioma

HiFiBiO Therapeuticsantibody_drug_conjugatePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

61 Active assets in the Mesothelioma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
Calcium folinate pentahydrate
Amphia Hospital
Phase 4B
Nivolumab
Orion Corporation, Orion Pharma
Phase 2B
Fludarabine
National Cancer Institute (NCI)
Phase 2B
Epirubicin
Genmab
Phase 2B

View all 50 →

Same molecule, other indications

rc48-adc is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →